Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Parmiani

Showing results (271-280 of 301) with videos related to

Pageof 31
Sort By:
La Ricerca in Clinica E in Laboratorio|January 1, 1986
Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studiesG Parmiani, M L Sensi, A Balsari, et al.
Cancer Research|September 29, 1998
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibodyC Melani, M Figini, D Nicosia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanomaE Bajetta, M Del Vecchio, R Mortarini, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I studyA Balsari, R Marolda, C Gambacorti-Passerini, et al.
Tumori|June 30, 1989
A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patientsN Cascinelli, F Belli, S Marchini, et al.
Cancer Research|February 2, 1999
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapyL Rivoltini, P Squarcina, D J Loftus, et al.
International Journal of Cancer|November 28, 2000
T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigensA J Bremers, S Andreola, E Leo, et al.
The Journal of Experimental Medicine|August 1, 1996
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.
Human Gene Therapy|October 20, 1996
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cellsF Arienti, J Sulé-Suso, F Belli, et al.
Folia Biologica|January 1, 1996
Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.
Pageof 31

Showing results (271-280 of 301) with videos related to

Sort By:
Pageof 31
La Ricerca in Clinica E in Laboratorio|January 1, 1986
Adoptive immunotherapy of cancer with immune and activated lymphocytes: experimental and clinical studiesG Parmiani, M L Sensi, A Balsari, et al.
Cancer Research|September 29, 1998
Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibodyC Melani, M Figini, D Nicosia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanomaE Bajetta, M Del Vecchio, R Mortarini, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1986
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I studyA Balsari, R Marolda, C Gambacorti-Passerini, et al.
Tumori|June 30, 1989
A phase II study of the administration of recombinant interleukin 2 (rIL-2) plus lymphokine activated killer (LAK) cells in stage IV melanoma patientsN Cascinelli, F Belli, S Marchini, et al.
Cancer Research|February 2, 1999
A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapyL Rivoltini, P Squarcina, D J Loftus, et al.
International Journal of Cancer|November 28, 2000
T cell responses in colorectal cancer patients: evidence for class II HLA-restricted recognition of shared tumor-associated antigensA J Bremers, S Andreola, E Leo, et al.
The Journal of Experimental Medicine|August 1, 1996
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35)D J Loftus, C Castelli, T M Clay, et al.
Human Gene Therapy|October 20, 1996
Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cellsF Arienti, J Sulé-Suso, F Belli, et al.
Folia Biologica|January 1, 1996
Cytokine-based gene therapy of human tumors. An overviewG Parmiani, F Arienti, J Sulé-Suso, et al.
Pageof 31